Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells
Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-18-0628
Full Text
Open PDFAbstract
Available in full text
Date
November 21, 2018
Authors
Publisher
American Association for Cancer Research (AACR)